Loading
Latest filing published 09 Aug 2023 for Quince Therapeutics, Inc., €8,979. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Margaret McLoughlin is a declared insider of IRulya Therapeutics Inc. (board member), with filings sourced from SEC (Form 4). Over a trading history stretching from 28 June 2021 to 8 August 2023, the count stands at 4 filings.
In open-market terms, that means 1 purchase worth €8,979 on one side and 1 sale worth €9,223 on the other. Netting one side against the other leaves €244 of net selling. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 2 option exercises. 2023 to date brings 1 purchase and no sales.
On 9 August 2023 came the latest disclosure, an open-market purchase for €8,979 in IRulya Therapeutics Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations